Hidenaga Yamamori
Overview
Explore the profile of Hidenaga Yamamori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
2933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yasuda Y, Ito S, Matsumoto J, Okada N, Onitsuka T, Ikeda M, et al.
Neuropsychopharmacol Rep
. 2025 Feb;
45(1):e70010.
PMID: 40011069
One of the challenges in diagnosing psychiatric disorders is that the results of biological and neuroscience research are not reflected in the diagnostic criteria. Thus, data-driven analyses incorporating biological and...
2.
Nakatochi M, Kushima I, Aleksic B, Kimura H, Kato H, Inada T, et al.
Psychiatry Clin Neurosci
. 2024 Oct;
79(1):12-20.
PMID: 39403837
Aim: Bipolar disorder (BD) is a common psychiatric disorder characterized by alterations between manic/hypomanic and depressive states. Rare pathogenic copy number variations (CNVs) that overlap with exons of synaptic genes...
3.
Miura K, Yoshida M, Morita K, Fujimoto M, Yasuda Y, Yamamori H, et al.
Mol Psychiatry
. 2024 Oct;
PMID: 39394456
Aberrant salience processing has been proposed as a pathophysiological mechanism underlying psychiatric symptoms in patients with schizophrenia. The gaze trajectories of individuals with schizophrenia have been reported to be abnormal...
4.
Yoshida M, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Iwase M, et al.
Sci Rep
. 2024 Feb;
14(1):4606.
PMID: 38409435
Abnormalities in visual exploration affect the daily lives of patients with schizophrenia. For example, scanpath length during free-viewing is shorter in schizophrenia. However, its origin and its relevance to symptoms...
5.
Yamazaki R, Matsumoto J, Ito S, Nemoto K, Fukunaga M, Hashimoto N, et al.
Neuropsychopharmacol Rep
. 2024 Feb;
44(1):206-215.
PMID: 38348613
Establishing a brain biomarker for schizophrenia is strongly desirable not only to support diagnosis by psychiatrists but also to help track the progressive changes in the brain over the course...
6.
Ito S, Ohi K, Yasuda Y, Fujimoto M, Yamamori H, Matsumoto J, et al.
Schizophrenia (Heidelb)
. 2023 Nov;
9(1):78.
PMID: 37935686
Schizophrenia is a psychiatric disorder that is associated with various social dysfunctions, including shorter work hours. To measure the degree to which psychiatrists adhere to guidelines for pharmacological therapy of...
7.
Matsumoto J, Fukunaga M, Miura K, Nemoto K, Okada N, Hashimoto N, et al.
Mol Psychiatry
. 2023 Aug;
28(11):4915-4923.
PMID: 37596354
According to the operational diagnostic criteria, psychiatric disorders such as schizophrenia (SZ), bipolar disorder (BD), major depressive disorder (MDD), and autism spectrum disorder (ASD) are classified based on symptoms. While...
8.
Okada N, Fukunaga M, Miura K, Nemoto K, Matsumoto J, Hashimoto N, et al.
Mol Psychiatry
. 2023 Aug;
28(12):5206-5216.
PMID: 37537281
Differential diagnosis is sometimes difficult in practical psychiatric settings, in terms of using the current diagnostic system based on presenting symptoms and signs. The creation of a novel diagnostic system...
9.
Kodaka F, Ohi K, Yasuda Y, Fujimoto M, Yamamori H, Hasegawa N, et al.
Int J Neuropsychopharmacol
. 2023 Jun;
26(8):557-565.
PMID: 37381793
Background: Clinician adherence to guideline recommendations in the pharmacological therapy of schizophrenia is important for favorable patient outcomes. To evaluate whether prescriptions followed the guidelines for pharmacological therapy of schizophrenia,...
10.
Sakai Y, Ito S, Matsumoto J, Yasuda Y, Yamamori H, Fujimoto M, et al.
Neuropsychopharmacol Rep
. 2023 Jun;
43(3):373-381.
PMID: 37377437
Aims: Schizophrenia is a psychiatric disorder presenting a lack of insight. Although insight changes over time, longitudinal studies of insight in schizophrenia are scarce. Furthermore, most previous studies on insight...